| Identification | Back Directory | [Name]
Irofulven | [CAS]
158440-71-2 | [Synonyms]
HMAF
MGI 114
NSC 683863
Irofulvene
(R)-Irofulven
[14C]-Irofulven
(-)-(HydroxyMethyl)acylfulvene
(6'R)-6'-Hydroxy-3'-(hydroxyMethyl)-2',4',6'-triMethylspiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one
Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (6'R)- | [Molecular Formula]
C15H18O3 | [MOL File]
158440-71-2.mol | [Molecular Weight]
246.3 |
| Chemical Properties | Back Directory | [Melting point ]
127-129° | [alpha ]
D25 -639° (c = 0.096 in ethanol) | [storage temp. ]
-20°C | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [color ]
Orange |
| Hazard Information | Back Directory | [Uses]
Semi-synrhetic antitumor agent derived from Illudin S. Inhibits DNA synthesis and induces apoptosis in tumor cells. Antineoplastic. | [Definition]
ChEBI: Irofulven is a member of cyclohexenones. | [in vivo]
(-)-Irofulven (7 mg/kg; i.p; on days 1-5 and 8-12) produces a statistically significant increase in the median survival of mice bearing tumor cells[2]. | Animal Model: | Male and female athymic BALB/c mice (nu/nu genotype, 6 weeks old or older) injected with human glioblastoma multiforme[2]. | | Dosage: | 7 mg/kg | | Administration: | i.p; on days 1-5 and 8-12 | | Result: | Was active against all tumor lines. |
|
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|